Japan Reports Two Deaths Possibly Linked To Erbitux
This article was originally published in PharmAsia News
Executive Summary
According to an adverse event report released by Japan's Ministry of Health, Labor and Welfare, a causal relationship associated with anticancer drug Erbitux (cetuximab) cannot be excluded in two reported heart failure deaths